Post Content
Is ACHC a good stock to buy? We came across a bearish thesis on Acadia Healthcare Company, Inc. on Valueinvestorsclub.com by burlap. In this article, we will summarize the bears’ thesis on ACHC. Acadia Healthcare Company, Inc.’s share was trading at $28.26 as of April 29th. ACHC’s trailing and forward P/E were 19.82 and 19.01 respectively according to Yahoo Finance.
Stokkete/Shutterstock.com
Acadia Healthcare (ACHC) presents a deteriorating credit profile that underpins a bearish view on its 7.375% unsecured notes due 2033, which appear mispriced relative to rising risks. The company operates 277 behavioral health facilities across the U.S., generating the majority of revenue from acute inpatient psychiatric hospitals, with additional contributions from specialty treatment, comprehensive treatment centers, and residential facilities, and relies heavily on Medicaid reimbursement.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Despite a sharp equity re-rating driven by operational setbacks, regulatory scrutiny, and negative publicity, credit spreads on its unsecured bonds have not adequately adjusted, leaving valuation disconnected from fundamentals. The company has incurred significant cash outflows, including a ~$400 million legal settlement, while continued lawsuits, elevated liability expenses, and weaker patient volumes have forced multiple EBITDA guidance cuts, with leverage rising from 1.9x to over 3.4x, and even higher on an adjusted basis.
Looking ahead, ACHC is likely to raise additional debt to fund ongoing cash burn, potentially through secured instruments that would structurally subordinate existing unsecured bondholders. At the same time, reimbursement pressures are intensifying as major Medicaid managed care organizations signal tighter utilization controls, while regulatory changes threaten the sustainability of favorable Medicaid State Directed Payments.
These combined pressures are expected to further weaken earnings and constrain free cash flow into 2026. With leverage potentially exceeding downgrade thresholds and legal liabilities persisting, the risk of credit rating downgrades remains elevated, creating asymmetric downside for unsecured creditors that the market has yet to fully price in.
Previously, we covered a bullish thesis on Tenet Healthcare Corporation (THC) by BlackSwanInvestor in December 2024, which highlighted the company’s strong ambulatory care segment growth, margin expansion, and balance sheet improvement through debt reduction and divestitures. THC’s stock price has appreciated by approximately 43.27% since our coverage. burlap shares a contrarian view but emphasizes on Acadia Healthcare’s deteriorating credit profile and rising regulatory and reimbursement pressures.